allogeneic anti-HLA-G NK cell therapy (Nkilt Therapeutics)

N/A

Report date: 2025/06/11 10:53:48

Base Information

Drug Nameallogeneic anti-HLA-G NK cell therapy (Nkilt Therapeutics)
Drug Alias NameHLA-G immune checkpoint inhibitor (Nkilt Therapeutics)CIR-NK cells therapy
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy
Mechanisms of ActionHLA class I histocompatibility antigen, alpha chain G inhibitorsNatural killer cells stimulantsT lymphocytes stimulants +[4] 
TargetsHLA class I histocompatibility antigen, alpha chain G
Therapy Area/IndicationsSolid tumoursLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNkilt Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesNkilt Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A